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eNOS: endothelial nitric oxide synthase
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NO: nitric oxide
VEGF: vascular endothelial growth factorINTRODUCTION
This report shows a positive therapeutic effect of
high-dose folic acid plus vitamins B6 and B12 on a
patient with palmar plantar pustulosis. Improvement
was likely through modulation of homocysteine
(Hcy) and nitric oxide (NO) synthase metabolic
pathways, and by inhibition of NF-kappa-B.CASE REPORT
The subject of this report signed a consent
approved by the Wayne State Institutional Review
Board for retrospective case review and publication.
A 56-year-old African American woman with no
previous skin conditions presented with a 2-month
history of blistering on both hands and feet. Her
medical history was significant for hypertension and
osteoarthritis, which were managed by triamterene/
hydrochlorothiazide, atenolol, acetaminophen/
codeine, and cyclobenzaprine. The patient had no
known allergies. She was not taking any vitamins,
was a smoker, and did not drink alcoholic beverages.
On physical examination, there were multiple
bilateral erythematous lesions with yellow scales
and pustules on her palms (Fig 1) and soles that
did not respond to previous treatments of hydro-
cortisone 1% cream. In addition, she had nail pitting
and some splinter hemorrhages. Clobetasol 0.05%
cream was prescribed for the initial diagnosis ofthe Department of Dermatology, Wayne State University,
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lic acid paradoxes: 1-2 mg folic acid plus B6 and B12 worsenspsoriasiform dermatitis but the patient only had mild
response to the treatment.
Later, she developed more papules and pustules
on the palms and plantar surfaces, and scalp involve-
ment began. Fungal culture from the scalp produced
negative findings. The patient was then given a
diagnosis of palmoplantar pustulosis and scalp
dermatitis. We offered her clobetasol 0.05% ointment
and ammonium lactate 12%, but her pustular lesions
persisted, coalescing into larger lesions on her
palmoplantar surfaces. Her vitamin B12 was within
the normal limit, as was her plasma Hcy level
(9.2 mol/L, normal levels 3.2-10.7 mol/L). We
decided to begin methotrexate (5 mg per week) and
folic acid (1 mg daily), with the plan of increasing the
methotrexate dosage to 10 mg if her blood work was
still within normal limits at her 2-week follow-up. At
the same time, we recommended the patient use
fluocinonide 0.05% cream to the affected areas.
Because of unforeseen logistic reasons, the
patient was unable to obtain the methotrexate. She
was then placed on daily folic acid (6mg), vitamin B6psoriasis and 5-7 mg daily folic acid plus B6 and B12 alone may
improve psoriasis but adding 5 mg acid plus B6 and B12 to
adalimumab cannot in general be recommended. Annual
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Fig 1. Palmar pustulosis on initial visit.
Fig 2. Palm after 6 weeks of clobetasol and then 12 weeks
of B vitamins and topical fluocinonide.
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success with such doses in patients with psoriasis.23
At the 2-week follow-up visit, the patient notified us
of a significant improvement.
After the significant improvement of her symp-
toms, the patient continued with daily folic acid,
vitamin B6, vitamin B12, and as-needed fluocinonide
and ammonium lactate. By her 3-month follow-up
visit the pustular lesions on her scalp, palms (Fig 2),
and plantar surfaces were gone. Interestingly, while
on the same oral regimen, 1 year later she was only
found to have small thin dyschromic plaques on the
plantar heel of her right foot without any pustules.
DISCUSSION
The amino acid Hcy is derived from methionine.
Methionine is converted to S-adenosylmethionine.
S-adenosylmethionine is the major biological methyl
donor required for the formation of proteins, nucleic
acids, epinephrine, melatonin, phosphatidylcholine,
and creatinine.1 These reactions are catalyzed by
various methyltransferases to form S-adenosyl-Hcy.
S-adenosyl-Hcy is converted by S-adenosyl-Hcy
hydrolase to simultaneously produce Hcy and
adenosine.2
Dietary folic acid forms 5-methyltetrahydrofolate
by the vitamin B2-dependent enzyme 5,10-
methylene tetrahydrofolate reductase. Hcy levels
can be reduced by reconversion to methionine by
remethylation using methionine synthase with
vitamin B12 as a cofactor and 5-methylhydrofolate
as a methyl donor, or degraded to cysteine by
transsulfuration using vitamin B6.2
Neutrophils are essential for histopathologic
diagnosis of psoriasis and for pustulosis palmaris
and plantaris.3 Hcy can increases neutrophil activity.Hyperhomocysteinemic subjects were found to have
elevated levels of epithelial neutrophil-activating
peptide, a regulator of polymorphonuclear white
blood cell or neutrophil chemotaxis and CXC
chemokines (the neutrophil activator interleukin-8/
CXC chemokine ligand 8).4,5 Hcy increases
superoxide anion release by neutrophils to the
extracellular medium. Hcy also increases intracel-
lular hydrogen peroxide production by neutrophil
migration and adhesion to human endothelial cells,
which promotes endothelial dysfunction from
decreased availability and activity of NO.6-10
In 2 studies, psoriasis patients’ plasma Hcy levels
correlated directly with Psoriasis Area and Severity
Index score and, when studied, Hcy levels inversely
correlated with folic acid levels.11,12
Improved blood vessel cell function measured by
flow-mediated dilatation correlates closely with the
reduction in free plasma Hcy regardless of folic acid
and vitamin B12 levels.13
However, with very high folic acid intake (5 mg/d,
but not 400 g/d) folic acid also improves
flow-mediated vasodilation.14 Flow-mediated vaso-
dilation is regulated by endothelial NO release.
Endothelial NO synthase (eNOS) synthesizes
NO. High-dose folic acid creates dimeric anti-
inflammatory (coupled) activity.14-17
Meta-analysis identifies inducible NO synthase as
a susceptibility locus for psoriasis. Etanercept-
cleared psoriasis skin has 87% less inducible
NO synthase.18 High-dose folic acid can reduce
inducible NO synthase.19
CARD-14 mutations are associated with palmar
plantar psoriasis through activation usually of
NF-kappa-B. CARD-14 is found on epidermal
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inflammatory doses of folic acid reduce NF-kappa-
B.16 Inhibition of NF-kappa-B is a mechanism for
control of psoriasis.22
Based on the backgroundmaterial behind our use
of the 3 B vitamins including high-dose folic acid, the
only unexpected outcome in this case was the
development of a small dyschromic plantar plaque
without recurrent pustules with continued use of
high-dose folic acid, and vitamins B6 and B12 seen at
1 year after initiation of this therapy.
More study is needed as shown elsewhere.24
Some patients with psoriasis who were already
taking adalimumab experienced flare with the 3 B
vitamins. Helicobacter pylori presence may strongly
inhibit folic acid absorption, increasing Hcy. More
likely if folic acid doses are absorbed that are not
high enough to create dimeric eNOS, proinflamma-
tory monomeric eNOS could be made or not
opposed especially if eNOS is not stabilized with
leptin. Psoriasis can be a disorder with elevated
vascular endothelial growth factor (VEGF). Hcy also
reduces expression of vascular endothelial growth
factor A, VEGF, and vascular growth factor receptor
2. Reducing Hcy with B vitamins therefore might
sometimes increase VEGF, which is another possible
reason for psoriasis-like disorders to flare.24
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